E.E. Geduld’s Heron Therapeutics HRTX Stock Holding History

E.E. Geduld’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-10,000	Closed	-$83K	–	256
2014 Q3	$83K	Sell	10,000 -6,362	-39%	-$59.2K	0.06%	189
2014 Q2	$202K	Sell	16,362 -8,638	-35%	-$103K	0.13%	183
2014 Q1	$348K	Hold	25,000	–	–	0.19%	133
2013 Q4	$223K	Buy	25,000 +15,000	+150%	+$134K	0.11%	190
2013 Q3	$67K	Hold	10,000	–	–	0.04%	235
2013 Q2	$72K	Buy	+10,000	New	+$72K	0.05%	212

Other funds holding HRTX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

E.E. Geduld's HRTX Position: Q4 2014 in Review

E.E. Geduld sold out of Heron Therapeutics (HRTX) in Q4 2014, closing a stake of 10,000 shares — an estimated $83K sold.

E.E. Geduld first reported a position in HRTX in Q2 2013 and held it in 6 quarters. The position peaked at $348K in Q1 2014. 64 funds tracked by Wall St. Rank hold HRTX as of Q4 2014.

E.E. Geduld reported no remaining Heron Therapeutics position as of Q4 2014 after selling out during the quarter.
E.E. Geduld sold 10,000 Heron Therapeutics shares in Q4 2014, an estimated $83K.
E.E. Geduld first reported a position in Heron Therapeutics in Q2 2013 and held it in 6 quarters.
E.E. Geduld's Heron Therapeutics position peaked at $348K in Q1 2014.
64 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2014.

Based on E.E. Geduld's 13F filing for Q4 2014, filed 30 Jan 2015.